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Activation of inflammasome signaling can produce harmful inflammation. In this issue of Immunity,
Yan et al. (2013) suggest that omega-3 fatty acids commonly found in marine oils can suppress activation
of NLRP3 and NLRP1b inflammasomes.Marine-derived omega-3 (u-3) polyunsat-
urated fatty acids (FA) such as
docosahexaenoic acid (DHA) and eico-
sapentaenoic acid (EPA) exhibit anti-
inflammatory properties (Oh et al., 2010),
but exact mechanisms for these proper-
ties are not fully understood. u-3 FAs
inhibit inflammatory cytokines such as
interleukin-1b (IL-1b) (Oh et al., 2010),
prompting interest in the idea that u-3
FAs can inhibit inflammasomes. In this
issue of Immunity, Yan et al. (2013)
provide insight into details of how such
an inhibition may occur.
Inflammasomes are intracellular pro-
tein complexes that serve as sensors
of microbial and endogenous cellular
insults (Davis et al., 2011; Vladimer et al.,
2013). Release of inflammasome-derived
IL-1b and IL-18 typically occurs in a
two-step process: triggering of a Toll-like
receptor (TLR) that primes the inflam-
matory response (‘‘signal 1’’) and intra-
cellular danger signals that initiate for-
mation of the inflammasome complex
(‘‘signal 2’’).
The NLRP3 inflammasome is acti-
vated by a large and diverse array of
pathogens, as well as endogenous and
exogenous sterile agonists and danger
signals. It is not surprising that NLRP3has been implicated to play a role in
several inflammatory disorders such as
gout and atherosclerotic disease by
potentially sensing uric acid crystals
and cholesterol crystals, respectively
(Davis et al., 2011; Duewell et al.,
2010). Recent evidence pointed to a
role for inflammasomes in initiating
obesity-induced inflammation and insu-
lin resistance related to type 2 diabetes
(Vandanmagsar et al., 2011; Henao-
Mejia et al., 2012) and other metabolic
disorders (Davis et al., 2011). The in-
crease in obesity and chronic inflam-
matory states underscores the need for
clinical therapeutics to prevent and treat
inflammation.
Because u-3 FAs can inhibit proin-
flammatory cytokines such as tumor
necrosis factor (TNF) and IL-1b (Oh
et al., 2010) and NLRP3 activation pro-
motes IL-1 b release, Yan et al. (2013)
set out to examine the possibility that
thwarting IL-1b release by u-3 FAs was
mediated by blocking inflammasome
activation. They confirmed that pretreat-
ing cells with DHA prior to stimulation
blocked caspase-1 activation and IL-1b
and IL-18 production. The u-3 FA EPA
and to a lesser extent the plant-derived
a-Linolenic acid (ALA) also blockedIL-1b, but u-6 and u-9 FAs had no
effect, indicating this inhibition is specific
for certain u-3 FAs.
DHA inhibited activation for all NLRP3
agonists tested, but failed to inhibit
activation induced by triggers of other
inflammasome components, such as
Salmonella (NLRC4 inflammasomes) or
DNA (AIM2 inflammasomes). However,
DHA also blocked activation of the
NLRP1b inflammasome, which is stimu-
lated by the microbial anthrax lethal
toxin. This finding suggested u-3 FAs
as specific inhibitors of NLRP3 and
NLRP1b inflammasomes.
The surface-exposed G protein-
coupled receptor 120 (GPR120) can
mediate anti-inflammatory effects of
DHA and EPA (Oh et al., 2010). By inhibit-
ing or decreasing expression of both
GPR120 and GPR40, DHA treatment no
longer repressed caspase-1 activation
and IL-1b release compared to partial
restoration of cytokine release when
GPR120 or GPR40 were individually in-
hibited. Therefore, u-3 FAs signal through
GPR120 and GPR40 to inhibit NLRP3
activation.
Additional mechanistic investigations
revealed that gene targeting of the
GPR120 downstream scaffold protein
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Figure 1. Activation and Inhibition of NLRP3 Inflammasome Signaling
Activation of the NLRP3 inflammasome is a two-signal process. ‘‘Signal 1’’ occurs by stimulation of TLRs
by microbial or endogenous ligands leading to NF-kB-dependent upregulation of pro-IL-1b. ‘‘Signal 2’’ is
provided by a wide array of NLRP3 inflammasome activators such as nigericin, anthrax lethal toxin,
b-amyloid, islet amyloid polypeptide, and cholesterol and monosodium urate crystals (data not shown).
Activated NLRP3 binds to pro-caspase-1 via the adaptor protein ASC, leading to caspase-1 cleavage
of pro- IL-1b and IL-18. Yan et al. (2013) show that the mechanism for u-3 FA inhibition of NLRP3-medi-
ated inflammation involvesu-3 FAs interacting with the GPR120 and GPR40 receptors. Subsequently, the
downstream scaffold protein ARRB-2 binds to GPR120 and GPR40, and the complex is internalized.
There are reports that this pathway inhibits ‘‘signal 1’’ at the level of TAB1 and TAK1 kinases to inhibit
NF-kB (Glass and Olefsky, 2012). Yan et al. (2013) also demonstrate here how ‘‘signal 2’’ is inhibited
when ARRB-2 directly associates with NLRP3 leading to inhibition of proinflammatory cytokine release
and inhibition of inflammation.
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of the inhibitory effects of DHA and
EPA on NLRP3 and NLRP1b. Cells from
animals deficient in ARRB2 showed
only partial abrogation of DHA inhibi-
tory activity, indicating that another
pathway in addition to GPR120-
GPR40-ARRB2 may also be involved in
NLR inflammasome inhibition induced
by DHA.
Interestingly, ARRB2 interacted with
NLRP3 and NLRP1b, and not NLRC4 or
AIM2, providing a likely reason why DHA
does not inhibit NLRC4 or AIM. DHA and
EPA treatment promoted interaction be-
tween NLRP3 and ARRB2 via GRP120
and GRP40. All together, these results
suggest that ARRB2 acts downstream of
GPR120 and GPR40 to inhibit inflamma-
some activation by binding to NLRP3 or
NLRP1b.
Interestingly, u-3 FAs play a more
global role in inhibiting inflammatory
cytokines and subsequently inflamma-
tory disease in an NLRP3-dependentmanner in vivo. Mice fed a high fat
diet (HFD) develop characteristics of
type 2 diabetes (T2D). HFD-fed mice
supplemented with DHA showed
remarkable decreases in T2D symptoms
compared to normal diet-treated mice
that were not further reduced in
NLRP3-deficient animals, indicating
that DHA prevents HFD-induced meta-
bolic disorder in a NLRP3-dependent
manner.
In summary, Yan et al. (2013) identified
a mechanism for how u-3 FAs exert
their anti-inflammatory properties via
inhibition of inflammasome activa-
tion. It is noteworthy that u-3FAs
may inhibit this activation at several
steps, by hampering both ‘‘signal 1’’
and ‘‘signal 2,’’ because u-3 FA inhibi-
tion of NF-kB signaling has also
been reported (Glass and Olefsky,
2012). Thus, several inflammatory sig-
naling pathways may be affected. This
study elegantly ties together the interplay
between dietary components and knownImmunity 3inflammatory pathways (Figure 1) and
could have implications for the pre-
vention and treatment of inflammatory
disorders.
One important issue raised by this
study is whether u-3 FAs would have
the same effect in human obesity and
inflammasome-driven inflammation as in
mouse studies and whether the intestinal
microbiota has a role in this setting
(Henao-Mejia et al., 2012). Also, treating
human patients with anti-inflammatory
agents can increase susceptibility to a
number of infections, and it remains to
be seen whether the same effect is
observed with u-3 FAs. It should be
noted that mouse studies suggest both
increased and decreased host resistance
to infections following fish oil feeding of
mice (Anderson and Fritsche, 2002),
although this issue is incompletely un-
derstood. Supporters of u-3 FAs pro-
mote their therapeutic potential for
several disease conditions, but some
larger meta-studies have failed to show
beneficial effects of u-3 FAs in condi-
tions like heart disease (Rizos et al.,
2012), thought to be influenced by u-3
FAs. One reason for variability between
different human population studies may
be that they may vary in how the FAs
are provided and how studies are
controlled. Are the same effects
achieved upon simple dietary changes,
u-3 FAs provided as an oil supplement,
or u-3 FAs provided as purified supple-
ments? More research is obviously
needed to further establish the role of
u-3 FAs in inhibiting inflammation in
human disease. In an important step
forward, Yan et al. provide us with a
framework of mechanistic insight into
how inflammation could potentially be
reduced in a variety of inflammatory
states.
Cod liver oil, anyone?REFERENCES
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In this issue of Immunity, Olson et al. (2013) demonstrate that circulating CD8+ memory T cells with an
effector-like phenotype, previously thought to be mostly senescent, provide robust protection from a
secondary pathogen challenge despite their poor secondary proliferative response.During the process of activation and dif-
ferentiation in response to infectious
pathogens, some CD8+ T cells acquire
the ability to persist into the memory
pool. Because these memory cells are
the key component of protective immu-
nity to intracellular pathogens, unraveling
the mechanisms behind their differentia-
tion and function has been of intense
interest. It is now appreciated that CD8+
memory T cells are heterogeneous, and
distinct subsets can be distinguished on
the basis of their trafficking patterns,
effector functions, tissue residence,
longevity, and proliferative capacity (Mu-
eller et al., 2013). Less is known about
the relative role of these subsets in pro-
moting protective immunity to a second
pathogen exposure.
Initially, effector and central memory
CD8+ T cells were defined on the basis
of unique expression of trafficking recep-
tors and the tendency to migrate to either
peripheral tissues or secondary lymphoid
organs (SLOs). However, although central
memory CD8+ T cells maintain the highest
proliferative capacity upon secondary
challenge, the relative protective capacity
of each subset seems to depend on the
nature of the secondary challenge (Bach-
mann et al., 2005a, 2005b; Wherry et al.,
2003). More recently, effector cytotoxicT lymphocytes (CTL) were segregated
into two subsets: those that expressed
high amounts of interleukin-7Ra (IL-7Ra)
and preferentially populated the long-
lived memory pool and those that ex-
pressed high amounts of the differentia-
tion marker KLRG1 and failed to establish
long-lived memory. KLRG1+ CTL were
demonstrated to largely consist of termi-
nally differentiated effector cells with little
proliferative capacity and poor long-term
survival (Joshi et al., 2007). Whereas their
numbers decline relative to other memory
CTL subsets during memory mainte-
nance, effector-phenotype memory CTL
that are at least in part phenotypically
distinct from conventionally defined
effector memory cells can persist for
several months after primary infection
(Mitchell et al., 2010). Nevertheless, the
long-held assumption has been that
these cells are senescent and unlikely to
play an important role in protection.
In this issue of Immunity, Olson et al.
(2013) employ a system of adoptive
transfer and heterologous immunization
to explore the per cell ability of effector-
phenotype memory CTL to mediate
protective immunity. In contrast to their
poor proliferative capacity, effector-
phenotype memory CTL displayed supe-
rior protective capacity to systemicsecondary challenges with either Listeria
monocytogenes or vaccinia virus.
Furthermore, these cells were greatly
enriched in the secondary memory CTL
pool following boosting without exhibit-
ing any loss in their protective capacity.
Because protective capacity and pro-
liferative capacity are clearly unlinked in
this system, what accounts for the en-
hanced protective capacity of effector-
phenotype memory CTL? One explana-
tion might be their enhanced cytolytic
function. Effector-phenotype memory
CTL expressed higher amounts of Gran-
zyme B than other memory subsets and
depended on Perforin for their protective
function, leading the authors to conclude
that their protective activity was depen-
dent on their direct cytolytic function.
Another contributing factor is likely to be
their localization. In support of this, the
authors show that within the spleen,
effector-phenotype memory CTL reside
primarily in the red pulp and accounted
for the majority of memory CTL in circu-
lation, whereas central memory CD8+
T cells reside primarily in the white pulp.
Because the red pulp is a primary point
of contact between CD8+ memory T cells
and blood-borne Listeria or Listeria-
infected macrophages (Baje´noff et al.,
2010), the ability of effector-phenotype
